Researchers developing gene targeting therapy to combat herpesFebruary 4th, 2009 - 4:47 pm ICT by IANS
Washington, Feb 4 (IANS) A new gene targeting therapy is being developed by researchers to combat herpes simplex virus.The approach uses a specially designed RNA enzyme to inhibit strains of the herpes simplex virus (HSV), by disabling a gene responsible for producing a protein involved in the maturation and release of viral particles in an infected cell.
The technique was successful in experiments with mice and rabbits, but further research is required before it can be attempted in people infected with herpes.
David Bloom, a virologist at the University of Floria College of Medicine (UFCOM), led the interdisciplinary research team investigating the new therapy.
The HSV-1 strain causes cold sores or fever blisters around the mouth, genital herpes, a deadly but rare type of encephalitis, and keratitis, a scarring of the cornea that leads to vision loss. HSV-2 is the more common cause of genital herpes.
Existing herpes treatments work because the active ingredients target viral building blocks, and become incorporated into the virus’ genetic material and shut down its ability to make copies of itself. In so doing, the drugs limit the severity of herpes lesions.
“They work pretty well, and they keep the disease in check, but there’s no real cure,” said Alfred Lewin, PhD, a molecular geneticist on the research team.
The UF team came up with a way to cut the virus’ RNA to prevent reactivation. By designing special enzymes called hammerhead ribozymes, the researchers were able to target a so-called “late” gene that releases its protein product relatively late after infection.
With late genes, partial corruption of the genetic material is sufficient to shut down virus production, as opposed to “early” genes, which would require total inactivation to hinder the process, said an UFCOM release.
“What I think is remarkable with the technology is its versatility - you can design ribozymes that will be effective against any pathogenic virus you’re interested in inhibiting,” said John M. Burke, professor of microbiology at the University of Vermont, who has studied the use of ribozymes for treating viral infections.
The work was published in the Journal of Virology.
- Diarrhea-causing bacteria turned into antiviral gene therapy agent - Feb 08, 2011
- Study associates herpes to Alzheimer's disease - Apr 05, 2011
- Genital herpes vaccine ineffective in women: Study - Oct 01, 2010
- Scientists unravel herpes virus protein structure - Jul 27, 2010
- Herpes vaccine edges closer to reality - Jun 16, 2010
- New discovery may lead to treatment for genital herpes infection - Jan 23, 2010
- New genetic strategy makes T-cells resistant to HIV infection - Jan 27, 2011
- New herpes vaccine shows promise - Mar 12, 2010
- Molecule engineered to attack HIV shows positive results - Jan 20, 2011
- Just four out of ten patients know they have genital herpes - Apr 12, 2011
- Why even treated genital herpes sores boost the risk of HIV infection - Aug 03, 2009
- How interferon-induced genes launch antiviral defenses - Apr 11, 2011
- Study offers potential new targets for novel anti-HIV drugs - Mar 26, 2011
- How H1N1 virus infects body - Dec 22, 2009
- New process to 'program' cancer cell death created - Sep 08, 2010
Tags: college of medicine, david bloom, fever blisters, genetic material, genital herpes, herpes lesions, herpes simplex virus, herpes treatments, hsv 1, hsv 2, interdisciplinary research team, molecular geneticist, partial corruption, patho, protein product, rare type, uf team, viral particles, virologist, virus production